Abstract
Autoimmune hepatitis (AIH) is a chronic inflammatory disease that is successfully treated with prednisone and/or azathioprine immunosuppressive therapy in 70% to 80% of patients. The remaining patients are intolerant or refractory to these standard medications. Budesonide, a synthetic glucocorticoid, undergoes a high degree of first-pass metabolism, reducing its systemic bioavailability, and has a 15-fold greater affinity for the glucocorticoid receptor than prednisolone. Budesonide may be a potentially useful systemic steroid-sparing immunosuppressive agent in the treatment of AIH. To review the Canadian experience using budesonide to treat AIH. Patients with AIH currently or previously treated with budesonide were identified through the Canadian Association for the Study of the Liver membership. Data were collected regarding their clinical and treatment history. A total of nine patients were identified. All patients were female, with an average age of 39 years (range 12 to 66 years). The indications for budesonide were adverse side effects of prednisone in two patients, noncompliance with prednisone and azathioprine in one patient and intolerance to azathioprine resulting in prednisone dependence in the remaining six patients...Continue Reading
Citations
May 20, 2009·World Journal of Gastroenterology : WJG·Albert J Czaja, Yusuf Bayraktar
May 26, 2009·Current Gastroenterology Reports·Maria T Greene, Peter F Whitington
Nov 19, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Eve A Roberts
Apr 6, 2012·Digestive Diseases and Sciences·Albert J Czaja
Jan 24, 2018·World Journal of Hepatology·Marianne Anastasia De Roza, Chee Hooi Lim
Dec 12, 2017·European Journal of Gastroenterology & Hepatology·Michele De Lemos-BonottoAndré L F Azeredo-da-Silva
Jun 3, 2009·Expert Review of Gastroenterology & Hepatology·Albert J Czaja
Jul 24, 2012·Alimentary Pharmacology & Therapeutics·P J Trivedi, G M Hirschfield
Nov 16, 2010·Journal of Gastroenterology and Hepatology·Dinesh JothimaniTim J S Cross
Sep 1, 2011·The Annals of Pharmacotherapy·Kenneth R Snider, Teresa G Potter
Jan 11, 2013·Autoimmune Diseases·Hind I Fallatah, Hisham O Akbar
May 15, 2020·Journal of Pediatric Gastroenterology and Nutrition·Justin ChenJennifer Vittorio
Jun 24, 2017·Journal of Pediatric Gastroenterology and Nutrition·Andréanne N ZizzoBinita M Kamath
Jan 3, 2014·Expert Opinion on Pharmacotherapy·Marina G Silveira, Keith D Lindor
Oct 4, 2017·World Journal of Gastroenterology : WJG·Benedetta Terziroli Beretta-PiccoliDiego Vergani
Oct 16, 2012·Expert Review of Gastroenterology & Hepatology·Albert J Czaja
Jan 29, 2010·Digestive Diseases and Sciences·Albert J Czaja
May 5, 2021·Hepatology International·Guiqiang WangShiv Kumar Sarin
Jun 25, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Diego VerganiGiorgina Mieli-Vergani
May 11, 2010·Gastroenterology·Albert J Czaja, Michael P Manns
Jul 10, 2010·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Luigi MuratoriMarco Lenzi